Composition, form of production and packaging
Solution for infusions is transparent, colorless.
1 l
sorbitol 60 g
sodium lactate 19 g
Sodium Chloride 6 g
calcium chloride in terms of dry matter 100 mg
potassium chloride 300 mg
magnesium chloride in terms of dry matter 200 mg,
in t.ch.
Na + 278.16 mmol
K + 4.02 mmol
Ca 2+ 0.9 mmol
Mg 2 + 2.1 mmol
Cl = 112.69 mmol
CH 3 CH (OH) COO = 175.52 mmol
theoretical osmolarity 900 mOsm / l
[PRING] water d / and.
200 ml - bottles of glass (1) - packs of cardboard.
400 ml - bottles of glass (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
Plasmo-replacing drug. Has rheological, anti-shock, detoxification, alkalizing effect. The main pharmacologically active substances are sorbitol and sodium lactate. In the liver, sorbitol is first converted to fructose, which is then converted into glucose, and then into glycogen. Part of sorbitol is used for urgent energy needs, the other part is stored as a stock in the form of glycogen. Isotonic sorbitol solution has a disaggregant effect and, thus, improves microcirculation and perfusion of tissues.
Unlike the bicarbonate solution, the correction of metabolic acidosis with sodium lactate passes more slowly as it enters the metabolism, without causing sharp fluctuations in pH. The effect of sodium lactate is manifested after 20-30 minutes after administration.
Sodium chloride is a plasma-substituting agent that exhibits detoxification and rehydration effects. Eliminates deficiency of sodium and chlorine ions at various pathological conditions.
Calcium chloride eliminates calcium deficiency. Calcium ions are necessary for the process of transmission of nerve impulses, reduction of skeletal and smooth muscles, myocardial activity, bone formation, and blood clotting. Reduces the permeability of cells and the vascular wall, prevents the development of inflammatory reactions, increases the resistance of the body to infections and can significantly enhance phagocytosis.
Potassium chloride restores the water-electrolyte balance. It exhibits a negative chrono- and batmotropic effect, in high doses - a negative foreign, dromotropic and moderate diuretic effect. Takes part in the process of carrying out nerve impulses. Increases the content of acetylcholine and causes excitation of the sympathetic part of the autonomic nervous system. Improves the process of skeletal muscle contraction in muscular dystrophy, myasthenia gravis.
PHARMACOKINETICS
Sorbitol is rapidly included in the total metabolism, 80-90% of which is utilized in the liver and accumulated in the form of glycogen. 5% is deposited in the tissues of the brain, heart muscle and skeletal musculature. 6-12% is excreted in the urine.
When introduced into the vascular bed of sodium lactate interacts with carbon dioxide and water, forming sodium bicarbonate, which leads to an increase in the alkaline reserve of blood. Only half of the injected sodium lactate (isomer L) is considered active, and the other half (isomer D) is not metabolized and excreted in the urine.
Sodium chloride is rapidly excreted from the vascular bed, only temporarily increasing the BCC. Do diuresis.
INDICATIONS
- to improve capillary blood flow for the prevention and treatment of traumatic, operating, hemolytic, toxic and burn shock, with acute blood loss, burn disease;
- infectious diseases, accompanied by intoxication, exacerbation of chronic hepatitis;
- sepsis;
- for preoperative preparation and during the postoperative period;
- to improve arterial and venous circulation for the prevention and treatment of thrombosis, thrombophlebitis, endarteritis;
Raynaud's disease.
DOSING MODE
Rheosorbylact В® is administered to adults in / in a jet or drip.
In case of traumatic, burn, postoperative and hemolytic shocks - 600-1000 ml (10-15 ml / kg body weight) once and repeatedly, first spray, then - drip.
In chronic hepatitis - 400 ml (6-7 ml / kg body weight) drip, repeatedly.
In acute blood loss - 1500-1800 ml (up to 25 ml / kg of body weight). In this case infusion of the drug Reosorbilact В® is recommended to be carried out at the pre-hospital stage, in a specialized ambulance.
In the preoperative period and after various surgical interventions - in a dose of 400 ml (6-7 ml / kg body weight) drip, once or repeatedly, daily, for 3-5 days.
In case of thromboobliterating diseases of blood vessels - at the rate of 8-10 ml / kg of body weight, drip, repeatedly, every other day. The course of treatment - up to 10 infusions.
Children under the age of 6 years are recommended to administer the drug in a dose of 10 ml / kg of body weight; at the age of 6 to 12 years - at a dose of half the dose for adults; children over 12 years of age, the dose of the drug is the same as for adults.
SIDE EFFECT
Possible: alkalosis, allergic reactions (skin rash, itching).
CONTRAINDICATIONS
- alkalosis;
- in cases where the infusion of large amounts of fluid is contraindicated (cerebral hemorrhage, thromboembolism, cardiovascular decompensation, arterial hypertension of the third degree);
- Hypersensitivity to the components of the drug.
With caution should prescribe the drug to patients with impaired liver function, peptic ulcer, hemorrhagic colitis.
PREGNANCY AND LACTATION
Data on the use of the drug Reosorbilact В® during pregnancy and during breastfeeding are absent.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
With caution should prescribe the drug to patients with impaired liver function.
APPLICATION FOR CHILDREN
Children under the age of 6 years are recommended to administer the drug in a dose of 10 ml / kg of body weight; at the age of 6 to 12 years - at a dose of half the dose for adults; children over 12 years of age, the dose of the drug is the same as for adults.
SPECIAL INSTRUCTIONS
The drug is used under the control of acid-base state and blood electrolytes, as well as the functional state of the liver.
Use with caution in patients with calculous cholecystitis.
OVERDOSE
Symptoms: there are phenomena of alkalosis, which quickly pass on their own, provided that the drug is discontinued immediately.
DRUG INTERACTION
Rheosorbylact В® can not be mixed with phosphate and carbonate-containing solutions.
Do not use as a carrier solution for other drugs.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored in a dry, protected from light, out of reach of children, at a temperature of 2 В° to 25 В° C. Shelf life - 2 years.
